Effect of Intratympanic Gentamicin Therapy in Meniere’s disease by Suresh, V
1 
 
DISSERTATION ON 
“EFFECT OF INTRATYMPANIC 
GENTAMICIN THERAPY IN MENIERE’S 
DISEASE” 
Submitted in partial fulfillment of the requirements for 
M.S. DEGREE BRANCH – IV OTORHINOLARYNGOLOGY 
Of 
THE TAMILNADU DR. M.G.R MEDICAL UNIVERSITY 
 
 
 
 
UPGRADED INSTITIUTE OF OTORHINOLARYNGOLOGY 
MADRAS MEDICAL COLLEGE 
CHENNAI – 600 003. 
APRIL  -2011 
 
2 
 
CERTIFICATE 
  This is to certify that this dissertation entitled                             
“EFFECT OF INTRATYMPANIC GENTAMICIN THERAPY IN 
MENIERE’S DISEASE” Submitted by Dr SURESH. V, appearing for M.S. 
ENT, Branch IV Degree examination in April 2011 is a bonafide record of work 
done by him     under my supervision in partial fulfillment of regulations of the 
Tamil Nadu Dr. M.G.R Medical University, Chennai.  I forward this to the 
Tamil Nadu Dr. M.G.R Medical University, Chennai, Tamilnadu, India.  
 
 
 
DIRECTOR & PROFESSOR,    DEAN, 
Upgraded Institute of Otorhinolaryngology,  Madras Medical College, 
Madras Medical College,     Government General 
Hospital, 
Government General Hospital,     Chennai – 600 003. 
  
Chennai – 600 003.  
3 
 
 
 
ACKNOWLEDGEMENT 
 I would like to express my sincere gratitude to                                                         
Prof. J. Mohanasundaram, M.D, DNB, Ph.D, The DEAN, Madras Medical                   
College, for having permitted me to conduct this study and to use the hospital              
material for this.  
 I am immensely grateful to Prof. Jacinth C. Cornelius, M.S. D.L.O., 
The Director & Professor, Upgraded Institute of Otorhinolaryngology, for his                       
valuable suggestions, encouragement and help in conducting this study. 
 I am greatly indebted to Prof. A. Muraleedharan, M.S., D.L.O.,                                        
Professor, Upgraded Institute of Otorhinolaryngology, who encouraged and                   
helped me throughout this study.  
 I am immensely thankful to Prof. G.Gananathan, M.S., D.L.O.,                
Professor, Upgraded Institute of Otorhinolaryngology, for his valuable guidance           
in conducting this study. 
 I am greatly thankful to Prof.   M.K.Rajasekar,   M.S., D.L.O., 
Professor,   Upgraded Institute of Otorhinolaryngology for helping me in this 
study. 
 I express my sincere thanks to all the Assistant Professors, for their                  
thoughtful guidance throughout the work. 
4 
 
         I thank the Secretary and Chairman of Institutional Ethical Committee, 
Government General Hospital and Madras Medical College, Chennai.  
         I thank all the Audiometricians and Speech therapists of the Upgraded 
Institute of Otorhinolaryngology for all their help and cooperation in conducting 
this study. 
         I thank all the paramedical staff and other staff of the Upgraded Institute            
of Otorhinolaryngology for all their help and cooperation in conducting this                   
study. 
 I thank all my colleagues and friends for their constant encouragement 
and valuable criticism. 
 I am extremely thankful to my family members for their continuous                
support. Above all I thank God Almighty for His immense blessings.  
 Last but not least, I express my gratitude for the generosity shown by all           
the patients who participated in the study.  
 
 
 
 
 
5 
 
                                               Contents 
 
Sl.No. Description Page 
1. INTRODUCTION 1 
2. AIMS OF STUDY 2 
3. REVIEW OF LITERATURE 3 
4. MATERIALS 34 
5. METHODOLOGY 36 
6. RESULTS & ANALYSIS 38 
7. DISCUSSION 48 
8. CONCLUSION 51 
9. BIBLIOGRAPHY 52 
10. PROFORMA 55 
11. ABBREVIATION 57 
12. MASTER CHART 58 
13. CONSENT FORM 66 
14. INSTITUITIONAL ETHICAL COMMITTEE 
CERTIFICATE 
68 
 
 
 
6 
 
                                           INTRODUCTION 
      Prosper Meniere was the first person to describe the symptoms of Meniere’s 
disease in1861. He proposed that the pathologic locus was in the labyrinth.  
      Meniere’s disease is a disorder of the inner ear. The symptom complex of 
Meniere’s disease consists of spontaneous, episodic attacks of vertigo, 
fluctuating sensorineural hearing loss, tinnitus, sensation of aural fullness.  
Meniere’s disease is often idiopathic and it can be caused by distention of 
endolymphatic space. Incidence of Meniere’s disease is more common in 
patient attending neuro otology clinic with dizziness. This disease has peak 
incidence in working age group between 30 to 60 years. 
       Gentamicin is an amino glycoside antibiotic that is preferentially toxic to 
the dark cell and hair cells of the vestibular labyrinth. It is less cochlea toxic 
when compared with other amino glycoside. 
       Now the gentamicin perfusion has emerged as a predominant therapy for 
incapacitating the vertigo of Meniere’s disease. 
    This study has been done to find out the effect of intratympanic gentamicin 
therapy in Meniere’s disease. 
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AIMS OF STUDY 
 To diagnose the patients with very definite and definite Meniere’s disease 
using electrocochleography. 
 To study the effectiveness of intratympanic gentamicin therapy in vertigo 
control. 
 To compare the intratympanic gentamicin therapy and oral therapy in 
Meniere’s disease. 
 To study the post intratympanic gentamicin therapy 
electrocochleographic changes. 
 To study the changes in hearing level, pre and post intratympanic 
gentamicin therapy. 
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REVIEW OF LITERATURE                                                    
ANATOMY OF INNER EAR: 
       The inner ear (or) labyrinth lies in the petrous part of the temporal bone. 
The inner ear has two part bony labyrinth and membranous labyrinth. Bony 
labyrinth consists of vestibule, semicircular canal and bony cochlea. Vestibule 
is a small ovoid bony chamber situated between the medial wall of the middle 
ear and lateral end of the internal auditory meatus. On the lateral aspect the 
fenestra vestibule is closed by the foot plate of stapes. On the medial aspect, it 
has depression for the saccule, utricle and cochlear duct. 
        There are three semi circular canals superior, lateral and posterior and they 
lies in planes at right angle to each other. Each canal has an ampullary end 
which opens independently in the vestibule. The non ampullary end of the 
lateral semi circular canal open in independently while that of posterior and 
superior semi circular canal unit to form a common opening called crus 
commune. 
       The angle formed by three semi circular canals is the solid angle. The 
truatman's’triangle is bounded by bony labyrinth anteriorly, sigmoid sinus 
posteriorly and superior petrosal sinus superiorly. 
THE STRUCTURE OF THE COCHLEAR DUCT: 
        The cochlear duct is subdivided by two longitudinally running membranes 
that separate three chambers, the scala tympani, scala media, and scala vestibuli. 
The organ of corti runs in a spiral along the floor of the scala media. The scala 
media in triangular section has the lower boundary formed by basilar 
membrane. Upper boundary is represented by the Reissner’s membrane. This 
runs obliquely with respect to the basilar membrane from the spiral limbus near 
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the modiolus, to the lateral aspect of the bony wall. The basilar membrane 
stretches across the cochlear duct from a bony shelf spiralling around the central 
bony modiolus, the osseous spiral lamina to a bony promontory, the spiral 
prominence. 
      The organ of corti extends across the upper surface of the basilar membrane 
from the spiral limbus to the Claudius’ cells. Underneath the basilar membrane 
is a layer of spindle shaped cells, the tympanic cells. The branching spiral vessel 
lies under the basilar membrane. 
       The longitudinal ridge of the spiral limbus is composed of a layer of 
interdental cells forming its upper surface and a main body containing blood 
vessels and connective tissue cells embedded in extracellar matrix. The side of 
the limbus facing the organ of corti is concave. The concavity is a lined sulcus, 
which borders the region of the organ of corti, containing the sensory cells and 
the supporting cells. An acellular flap, the tectorial membrane forms a thin layer 
over the weakly convex top of the spiral limbus and projects over the inner 
sulcus and across the organ of corti. 
 Reissner’s membrane consists of two layers of cells separated by a 
basement membrane. The layer facing into the scala tympani is the mesothelial 
cell layer. Facing the scala media is the endothelial cell layer.  
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The cells within each layer are joined by tight junctions who act as an 
impermeable barrier to ions and small molecules  
The lateral wall consists of the stria vascularis composed of three layers of 
cells. There are marginal cells facing the scala media, the intermediate 
cells and the basal cells. The marginal cells have tight junctions 
connecting them together. 
 The cells of the lateral wall contain a variety of ion pumps, enzymes 
and transport proteins associated with homeostatic mechanis ms for 
maintaining the ionic composition of the fluids of the cochlea 18. 
THE FLUID SPACE OF COCHLEA 
         The principal division of the fluid space in the cochlea is the perilymphatic 
space within the scala vestibuli and scala tympani, and the endolymphatic space 
within the scala media. The walls surrounding the endolymphatic space have 
occluding tight junction between the cells, obstructing the movement of ions in 
and out of the cell. The perilymphatic space surrounds the membranous 
labyrinth and opens into the cerebrospinal fluid by the cochlear aqueduct. The 
endolymphatic space is joined to the endolymphatic sac by means of the 
endolymphatic duct. 
FORMATION AND ABSORPTION OF THE ENDOLYMPH AND 
PERILYMPH     
ENDOLYMPH 
 The endolymph of the cochlea is formed by the stria vascularis, which are 
secreting cell. Under the light microscope, the cells of the stria vascularis can be 
divided into superficially located darkly staining cells, called the marginal cells, 
and more lightly staining the basal cells. Under the electron microscope it can 
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be seen that the marginal cells have long infoldings on their basal edge, across 
which most of the energy-consuming pumping of the stria vascularis takes 
place. The stria vascularis has a high concentration of N+/K+-ATPase, adenyl 
cyclase,carbonic anhydrase, and oxidative enzymes associated with active 
pumping of ions and transport of fluid into the endolymph. 
           The endolymphatic sac contributes to the homeostasis of the endolymph. 
The cells in the sac are columnar shape and containing long microvilli on the 
luminal surface, with many pinocytic vesicles and vacuoles. It removes the 
cellular debris and foreign material from the endolymph. Obliteration of the 
endolymphatic sac and duct causes endolymphatic hydrops. 
PERILYMPH 
        The site of production of perilymph is controversial. The perilymph is not 
a simple ultrafiltrate of plasma. The k+, glucose, aminoacids and proteins are 
higher concentration than the CSF. When the cochlear aqueduct is blocked only 
the concentration of scala tympani is rises, the scala vestibule concentration is 
the same. It suggests that the perilymph of scala vestibuli primarily originate 
from the plasma, while the perilymph of scala tympani originates from both csf 
and plasma. 
THE COMPOSITION AND ELECTRICAL POTENTIAL OF THE 
COCHLEAR FLUID 
Endolymph 
    The endolymph has a high k+ content and low Na+ content resembling 
intracellular fluid. The electrical potential is strongly positive ranging from +50 
to +120 m V with respect to plasma. The higher values found in the basal turn 
and also near the stria vascularies 2. The positive endocochlear potential is 
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directly dependent on Na+K+-ATPase in the marginal cells of the stria 
vascularis 18. 
Perilymph     
     The values are in the range of normal extracellular concentration, although 
the K+ concentration are somewhat higher in scala vestibule than scala tympani. 
The electrical potential of the scala tympani is +7 m V found to be little positive 
than that of the scala vestibule +5 mV. 
ULTRASTRUCTURE AND FUNCTION OF HAIR CELL     
Outer hair cell 
      The apical part of the outer hair cell is a sensory end, bearing the 
stereociliary bundle. The basal end consists of the synaptic pole where the cell 
connects the afferent and efferent nerve fibers. 
The apical surface is flattened, whilst the cell body is cylindrical. The stereocilia 
are arranged in five rows. The rows increase along the bundle, like a staircase. 
The outer hair cells in the top of the bundle are in the contact with the tectorial 
membrane, while inner hair cell is standing free. 
The stereocilia are cylindrical, narrowing sharply having beveled tip in the 
intermediate rows. The stereocilia contain a core of actin filaments cross linked 
by actin associated proteins, plastin and espin. The stereociliary membrane 
contains proteins associated with calcium control (plasma membrane calcium 
ATPase) and mechanosensitivity (mechanoelectrical transduction channel). 
There may also be other channels, ATP gating receptor and acid sensing 
channel. 
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During transduction, they are gated mechanically by movements of hair bundle. 
Deflections of bundle are driven by the motion of basilar membrane-organ of 
corti complex that causes shearing of the tectorial membrane parallel to the 
surface of the organ of corti. This in turn directly drives the outer hair cell 
stereociliary bundle backward and forwards. Deflections in the direction of 
increasing stereociliary height depolarize the outer hair cell by causing the 
channels to open and allow influx of cations. Whilst opposing deflections 
hyperpolarize the hair cell by closing the channel 19. 
Inner hair cell 
    The inner hair cells have a flattened or slightly concave apical surface, and a 
flask shaped cell body with a wide center tapering basally and apically. The 
stereociliary bundle consists of three to four rows. Each rows of stereocilia are 
similar height. The stereocilia are cylindrical actin- containing structures as in 
the outer hair cell. The stereocilia are again connected together by filamentous 
lateral links, which binds both sideways and across the rows. The process of 
transduction by inner hair cell is similar to that of outer hair cell. 
ULTRASTRUTURE OF THE VESTIBULAR ORGAN  
     The vestibular organ consists of a delicate system of membranous ducts 
containing sensory epithelia or mechanoreceptors important for the sense of 
gravity and balance. The sensory epithelium is located in the three ampullae of 
the semicircular canals and in the macula of the saccule and utricle. 
  The vestibular organs contain endolymph and are surrounded by perilymph 
fluid. The membranous system or labyrinth due to its complexity is connected 
to the cochlea through the thin reunion duct. The various portion of the 
vestibular organ are interconnected by small canals. The utricular and saccular 
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duct merge and to form the utriclosaccular duct. This canal runs posteriorly and 
enters the internal aperture of the bony vestibular aqueduct. 
      It forms the endolymphatic duct which widens triangularly within the 
posterior surface of the petrous bone into the endolymphatic sac. 
The endolymphatic sac ends blindly within a dural duplicature in the posterior 
cranial fossa in close association with the sigmoid sinus and venous drainage of 
the brain. The endolymphatic sac consists of both an intraosseous and an 
extaosseous portion.  The surface of the intraosseous portion of the sac is 
irregular and tubular, while the surface of the extaosseous portion is usually 
more smooth and flat. 
The endolymphatic sac and duct, which are closely related to the brain, are 
involved in the reabsorption of endolymph and regulation of perilymph 
pressure. 
Vestibular sensory cells, type I and type II 
  The type I cells are flask-shaped and surrounded by the terminal end of 
the afferent fiber of the vestibular nerve. Many of the calyces have collateral 
extensions that end on type II hair cells. Type II hair cells synapse with these 
collaterals and also directly with the outer membrane of calyces surrounding 
type I hair cells. Efferent nerve endings also terminate on the afferent nerve 
calyce and on type II hair cells. 
 Type I cells, which are found only in birds and mammals, correspond to 
the inner hair cells of the organ of Corti. Some of the sensory cells are low 
threshold mechanoreceptors, showing a high degree of adaptation being 
presynaptic to the large-diameter myelinated neurons in the vestibular nerve. 
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These highly adaptive cells are thus considered to be associated with neurons 
showing an irregular discharge pattern. Type II cells, which are thought to be 
phylogenetically older, resemble outer hair cells of the organ of Corti. They are 
cylindrical in shape, but have the same arrangement of stereo-and kinocilia as 
the type I cells. The upper surface of the hair cell contains approximately 70 
stereocilia and one kinocilium arranged with the longest stereocilia positioned 
adjacent to the kinocilium. The stereocilia in the macula are a few microns long, 
while in the crista they measure up to over 35 um. The stereocilia contain actin 
filaments.  All the cilia within a bundle move together as if joined to one 
another. Labelling for electron microscopy with polycationic ferritin reveals that 
the membrane surrounding the cilia has a surface coat of negatively charged 
molecules. The upper surface of the cell contains a thicker region, called the 
‘cuticular plate’ into which the stereocilia extend their rootlets.  
SUPPORTING AND ‘DARK’ CELLS 
 The sensory cells are surrounded by supporting cells whose function may 
be partly secretory in nature. They may provide support and insulation for the 
sensory cells and may also form precursor cells for sensory hair cells. 
 The membranous labyrinth contains so-called ‘dark’ cells in all sensory 
epithelia, except the saccule. The cells have an irregular surface and resemble 
the marginal cells of the stria vascularis. In addition melanocytes are often 
associated with the dark cells, which is similar to the situation in the stria 
vascularis of the cochlea1. These cells are important for the development and 
maintenance of the unique chemical composition of the endolymph thereby 
playing a role for the proper function of the electric activity of the sensory cells 
and initiating conductive neural responses of afferent nerves.  
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SACCULE AND UTRICLE 
      The utricle is oblong, irregular and slopes anteriorly upwards at an angle of 
approximately 300. It lies superior to the saccule. The macula utriculi are the 
largest and lie mostly in the horizontal plane located in the dilated superior 
portion of the utricle. The macula utriculi contain approximately 33,000 hair 
cells. The saccular macula contains approximately 18,000 hair cells. Overlying 
the neuroepithelium is a calcareous material consisting of a multitude of small 
cylindrical and hexagonally shaped bodies with pointed ends, usually named 
otoconia. These otoconia are anchored and partially embedded in a gelatinous 
substance forming the otoconial membrane.  
The hair process project in to the otoconial membrane and are displaced 
mechanically by the otoconial mass relative to the sensory epithelium.  
FUNCTION OF THE AMPULLA AND CUPULA 
 The afferents in the horizontal canal are stimulated, when endolymph 
flows against the utricle. The two vertical canals are stimulated, when 
endolymph flows against the ampulla. The sensory epithelium on the crista is 
covered by gelatinous mass called the cupula. The cupula in the ampulla of the 
semicircular canal helps in transferring endolymph fluid movement stimuli to 
the hair cells. This gives rise to kinetic reflexes.  
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MENIERE’S DISEASE 
 This is common disorder of the inner ear and is sometimes also referred 
to by its etiopathological nomenclature endolymphatic hydrops. However, the 
two terms are not synonymous.   
DEFINITION 
 Meniere’s disease is a disorder characterized by spontaneous attack of 
vertigo, with associated fluctuating sensorineural hearing loss, tinnitus, and 
aural fullness. 
 ETIOPATHOGENESIS 
 Endolymph may be either excessively or inadequately resorbed resulting 
in expanstion of the endolymphatic space. Endolymphatic hydrops typically 
involves the pars inferior of the labyrinth (comprising the saccule and cochlea). 
Saccular hydrops may range from mild to severe, based on the degree of 
membrane distention toward the stapes footplate. Cochlear hydrop is bowing of 
the Reissner membrane into the scala vestibule. Severity of cochlear hydrops 
also varies according to the degree of convexity toward the scalar wall of 
modiolus. 
 The degree of distention appears to be related to the mechanical 
compliance of membranous components of the inner ear, with high compliance 
(mechanically weaker membranes) in the scala, lower compliance 
(mechanically stronger membranes) in the semicircular canal 13.  
 The distention of the endolymphatic duct causes rupture of the 
membranes, this has been observed throughout the labyrinth. Membrane rupture 
allows the potassium rich endolymph to leak into the perilymphatic space and 
contact the basal surface of the hair cells as well as the eighth cranial nerve. 
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Initial excitation then subsequent inhibition of the hair cells manifest as a 
direction changing nystagmus and episodic vertigo 12. 
 Long term declines in auditory and vestibular function may be the result 
of repeated exposure of the vestibular hair cells to toxic levels of potassium 
enriched perilymph. The sparse nerve endings on the basal surface of type II 
hair cells provide decreased protection against harmful ionic changes in the 
perilymph 13.  
 Alternatively, the hydrops itself may occur in an episodic manner, as a 
result of sudden increase in the secretory function of the stria vascularis or the 
spontaneous obstruction of the endolymphatic sac. Hydropic distention may 
then cause a mechanical deflection of the macula and crista of the otoliths and 
semicircular canals, respectively, and thus vestibular hair cells depolarization 
leading to the sensation of vertigo 15. Long term changes to the neuro sensory 
function of the vestibular apparatus may be the consequence of increased 
hydrodynamic pressure, causing increased vascular resistance, compromised 
blood flow, and chronic ischemic injury.  
SYMPTOMS 
1. Vertigo : Vertigo occurs in spells that lasts from 20 minutes to 24 hours, and 
is usually accompanied by nausea and vomiting. In between two attacks, the 
patient does not have any significant vertiginous problems.  
2. Deafness : Initially low frequency sounds is lost and gradually increases in 
intensity middle and high frequency sounds. The deafness is usually more 
marked during the attacks (fluctuating in nature) and Sensorineural type. 
3. Tinnitus : A subjective tinnitus is present in most patients during the attacks 
of vertigo. It is perceptible in the intervening period also.  
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4. Aural Fullness: The sensation of fullness of the ear usually starts 
immediately prior to the vertiginous attacks. But the ear fullness subsides after 
the attack and is usually absent in the intervening period 17. 
AAO-HNS CLASSIFICATION 
VERY DEFINITE MERIERE’S DISEASE 
 The patient has had at least two attacks of sudden vertigo has lasted more 
than 20 minutes but less than a day along with Deafness, Tinnitus, Aural 
fullness, Glycerol dehydration test positive , EcochG positive 
DEFINITE MENIERE’S DISEASE; 
 Episodic vertigo, Deafness, Tinnitus, Aural fullness, Positive glycerol 
positive test, Typical EcochG finding not present  
PROBABLE MENIERE’S DISEASE; 
 Only one episode of severe vertigo of less than 24hrs ,but more than 
20mts along with Tinnitus, Aural fullness, Audiometric evidence of 
hearing loss 
POSSIBLE MENIERE’S DISEASE  
 Episodic vertigo of the Meniere type without hearing loss, or sensoineural 
hearing loss, fluctuating or fixed, with disequilibrium but without 
definitive episodes. 
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AAO-HNS CRITERIA FOR MENIERE’S DISEASE 
Vertigo 
a. Any treatment should be evaluated no sooner than 24 months. 
b. Formula to obtain numeric value for vertigo; average number of 
definitive spells/ months in a 24 month after therapy× 100=numeric 
value. 
c. Numeric value scale 
  Numeric value scale        control level                            class 
   0                     complete control of definitive spells         A              
 41-80                 limited control of definitive spells           B 
81-120        insignificant control of definitive spells           C 
>120                                                                                    D 
Secondary treatment initiated                                              E 
Disability 
a) No disability 
b) Mild disability- intermittent or continuous dizziness/ unsteadiness that 
precludes working in a hazardous environment. 
c) Moderate disability- intermittent or continuous dizziness/ unsteadiness 
that result in a sedentary occupation. 
d) Severe disability- symptoms so severe as to exclude gainful employment. 
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Hearing 
Hearing is measured by a four frequency pure tone average (PTA) 500Hz, 1 
KHz, 2 KHz, and 3 KHz. 
Pretreatment hearing level: worst hearing level 6 months prior to surgery. 
Post treatment hearing level: poorest hearing level measured 18-24 months after 
institution of therapy. 
Hearing classification: 
 Unchanged=10d B PTA ,15% SD 
 Improved >10 d B PTA >15% SD 
 Worse >10 d B PTA worsened >15% SD worsened. 
Hearing level 
Stage       Four tone averages (d B) 
1 >25 
2 26-40 
3 41-70 
4 >70 
 
Functional level scale 
This is subjective scale determined by patient 
1. My dizziness has no effect on my activities at all. 
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2. When I am dizzy, I have to stop for a while, but it soon passes and I can 
resume my activities. I continue to work, drive, and engage in any 
activity I choose without restriction. I have not changed any planes or 
activities to accommodate my dizziness. 
3. When I am dizzy I have stop what I am doing for a while, but it does 
passes and I can resume my activities. I continue to work, drive, and 
engage in most activities I choose, but I have had to change some plans 
and make some allowance for my dizziness. 
4. I am able to work, drive, travel, and take care of a family or engage in 
most activities, but I must exert a great deal of effort to do. So, I must 
constantly make adjustments in my activities and budget my energies. I 
am barely making it. 
5. I am unable to work, drive, or take care of a family. I am unable to do 
most of the active things that I used to do. Even essential activities must 
be limited. I am disabled. 
6. I have been disabled 1 year or longer and/or I compensation because of 
my dizziness or balance problem. 
AAO-HNS STAGING FOR MENIERE’S DISEASE 
STAGE I: PTA 0-25dB, the tinnitus may or may not be perceptible, sense of 
fullness, vertigo once or twice a year. 
STAGE II: PTA 25- 35dB, the tinnitus is mild and perceptible only during 
concentration, the sense of aural fullness, attack of vertigo 3-4 per year. 
STAGE III: PTA 36-50dB, the tinnitus more frequent, aural fullness, attack of 
vertigo 6-15 per year. 
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STAGE IV: PTA 50-65dB, the tinnitus is constantly present; sense of aural 
fullness is persistent, vertigo 3-4 per week. 
STAGE V: PTA 66-75dB, the tinnitus is constant, sense of aural fullness is 
persistent and attack of vertigo is very frequent. 
 STAGE VI: more than 75dB tinnitus and vertigo incapacitating, sense of aural 
fullness is persistent. 
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AUDIOVESTIBULAR TESTING IN PATIENTS WITH MENIERE’S 
DISEASE 
AUDIOMETRIC TESTING 
Hearing loss is predominantly sensorineural, fluctuating and progressive. The 
hearing loss tends to involve the low frequencies early in the course of the 
disease. Higher frequencies may also be affected, and some have observed a 
peak, or inverted-V, audiogram in patients with MD. The hearing loss tends to 
flatten and become less variable. There is no audiometric configuration that can 
be considered characteristic of MD. Fluctuation of pure tone thresholds, word 
recognition, or both is commonly noted. In patients with long-standing MD 
(>10 years), the average pure tone threshold in the affected ear stabilizes at 
about 50 dB, and the mean word recognition score reaches a minimum of 50%, 
Profound hearing loss occurs in only 1% to 2% of patients. The sensorineural 
hearing loss is cochlear in etiology, with associated distortion, loudness 
recruitment, and a reduction of word recognition scores in proportion to the 
pure tone average.   
LOUDNESS RECRUITMENT 
The most straightforward test of loudness recruitment is the alternate binaural 
loudness balance test (ABLB).  Recruitment will show evidence of cochlear 
pathology. 
SHORT INCREMENT SENSITIVITY INDEX (SISI) 
            SISI test is used to differentiate a cochlear from retrocochlear lesion. In 
this test, a continuous tone is presented 20 dB above the threshold and sustained 
for about 2 minutes. Every 5 seconds, the tone is increased by 1 dB and 20 such 
blips are presented. Patient indicates the blips heard. In conductive deafness, 
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SISI score is more than 15%; it is 70%-100% in cochlear deafness; and 1-10% 
in nerve deafness. 
TONE DECAY TEST 
          It is used to detect retrocochlear lesions. Normally, a person can hear a 
tone continuously for 60 seconds. In nerve fatigue, he stops hearing earlier. A 
decay more than 25 dB is diagnostic of a retrocochlear lesion. 
VESTIBULAR TESTING 
Vestibular test results are not included in the 1995 AAO-HNS Guidelines 
for the Diagnosis and Evaluation of Therapy in MD, and, strictly speaking, are 
not necessary for the diagnosis of MD.  
CALORIC TESTING   
Caloric testing represents a non physiologic, low-frequency stimulation 
of the horizontal semicircular canal. It is the only test in the standard vestibular 
test battery that provides lateralizing information. This common vestibular test 
abnormality is reported in up to 50% to 66% of MD patients. This leaves a 
significant proportion of patients with MD who will have no evidence of 
pathology on caloric testing. Complete loss of vestibular function as manifested 
by absent caloric response to ice water irrigation need not be pursued as a 
therapeutic end point in intratympanic gentamicin therapy, as it is not required 
for vertigo control in MD. 
VESTIBULAR EVOKED MYOGENIC POTENTIALS 
Vestibular evoked myogenic potential (VEMP) testing is a more recent addition 
to the MD diagnostic armamentarium. The VEMP is obtained by measuring the 
relaxation of the sternocleidomastoid muscle (SCM) in response to an ipsilateral 
auditory stimulus.  Brief high-intensity monaural clicks or tone-bursts produce a 
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large, short-latency   inhibitory potential (VEMP) in the tonically contracted 
ipsilateral SCM. Although   the exact neural pathway is still not fully clear, the 
VEMP is considered to be a vestibulocollic reflex with the afferent limb arising 
from sound-responsive sensory cells in the saccule. The afferent signal is 
conducted centrally via the inferior vestibular nerve, and efferent signal is 
conducted via the vestibulospinal track to produce inhibitory post- synaptic 
potentials in cervical motor neurons. Normal responses are composed of 
biphasic (positive-negative) waves.  
VEMP testing is a useful to reveal saccule dysfunction. After the cochlea, the 
saccule is the second most common site of hydrop changes in temporal bones of 
patients with MD.  
ELECTROCOCHLEOGRAPHY 
           The cochlea receives the sound from the middle ear and converts it into 
electrical energy which then passes through the auditory nerve to the higher 
center in the brain. The electrical activity generated by the cochlea and in the 
auditory nerve can be measured by a system called electrocochleography. The 
parameters measured by ECochG are cochlear microphonic (CM), the 
summating potential (SP) and the auditory nerve compound action potentional 
(AP). The cochlea microphonic is the electrical activity occurring in the cochlea 
in response to the sound stimulus, the compound action potential is the 
electrical activity obtained in the auditory nerve. The summating potential is a 
complex measurement of many electrophysiological parameters taken together. 
           The technique is similar to ABR measurement, in that an auditory 
stimulus is presented to the test ear and an electrical response is recorded. In the 
case of ABR, the recording electrode is placed on the scalp, and the response of 
the auditory nerve and brainstem is measured. The pertinent time epoch consists 
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of the first 10 ms after stimulus presentation. In the case of EcochG, the 
recording electrode is placed as close to the cochlea as possible (near-field 
recording), and the response is measured from the cochlear hair cells and 
auditory nerve. The epoch of interest is generally within the first 3 ms following 
stimulus presentation. 
  Optimally, the measurement of these potentials is performed with an 
electrode placed as close as possible to their source to maximize response 
amplitude. Such near-field recording can be performed with a silver ball 
electrode placed on the round window membrane. Because this requires surgical 
exposure of the middle ear, it is not widely accepted for routine outpatient 
clinical applications. An alternative method is the use of a transtympanic 
promontory needle electrode referenced to an electrode external to the ear 
(forehead or tragus). Less invasive recording may be performed with electrodes 
placed in the external ear canal or on the surface of the tympanic membrane. 
The latter is gaining in popularity because of ease of placement and the clarity 
and amplitude. This electrode is positioned gently onto the central portion of the 
lateral surface of the TM under microscopic visualization. Recording from the 
external auditory meatus skin (EAM) can be accomplished with an expanding 
leaf-type surface electrode or a foam insert ear phone covered with gold foil. 
Although these electrodes are simple to place, the response amplitudes are 
considerably degraded and the noise levels are higher compared with TM 
electrodes. 
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ELECTROCOCHLEOGRAPHIC ABNORMALITIES IN PATIENTS 
WITH MD 
ECochG is often used in the clinical investigation of hydrops conditions 
of the cochlea, such as MD, but its diagnostic utility and interpretation remain 
topics of controversy. It is believed that the presence of hydrops increases the 
amplitude of the SP by affecting the elasticity and resting position of the basilar 
membrane.. Endolymphatic hydrops is associated with relatively larger SP/AP 
values. Most investigators have used a value of 0.3 to 0.4 as the upper limit of 
normal for SP/AP, and have found that approximately two-thirds of MD ears 
have abnormal ECochG results. Only 76% of patients with MD had abnormal 
ECochG 22. 
DEHYDRATION TESTING 
      The most distinctive test is the Glycerol dehydration test in which the 
patient is made to ingest glycerol (1.5 cc/kg of body weight) and the air-
conduction audiometric test is repeated at every half to 1 hour intervals. If the 
patient suffers from Meniere’s disease then an improvement of hearing level 
will be obtained by 10-15 dB in most frequencies, especially the lower 
frequencies. For the glycerol test to be considered as positive there should be a 
hearing improvement of at least 5 dB in three consecutive octaves. This 
improvement of hearing threshold occurs due to the dehydrating effect of the 
glycerol, on the endolymphatic fluid in the inner ear. The dehydration brought 
about by the glycerol decreases the volume of the endolymph and reverses the 
hydrops which improves the hearing. 
Side effects may include headache, nausea, dizziness, diarrhea, thirst, emesis, 
and dieresis 21. 
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MEDICAL THERAPY FOR MENIERE’S DISEASE 
Treatment of acute exacerbations 
        Acute attack of Meniere’s disease is characterized by acute rotational 
vertigo, transient fluctuations in hearing, tinnitus, and aural fullness. Initial 
management focuses on excluding other conditions that can present with same 
symptoms, including vestibular neuritis, migraine, cerebral vascular events, 
multiple sclerosis and tumors. Acute management of Meniere’s disease is 
mainly symptomatic control. Vestibular suppressants can be used 7. 
Low-salt diet and lifestyle modification 
       It has been believed that a high salt diet can influence the osmotic gradients 
in the inner ear.  Levels of salt restriction range from 2g per 24hrs down to 1g 
per 24hrs. There is no strong evidence exists to support the role of salt 
restriction alone in reducing the frequency or severity of symptoms from 
Meniere’s disease. 
Diuretics 
       Diuresis reduces the amount of endolymphatic hydrops by reducing the 
extracellular fluid in the body. Hydrochlorothiazide is perhaps the most widely 
advocated, although frusamide and spiranolactone have their supports. There is 
no clear scientific evidence exists to support their efficacy. 
Betahistine 
        Cochlear vascular insufficiency as a result of autonomic dysfunction has 
been proposed as a cause of MD. Betahistine has been proposed as a treatment 
because of its theoretic vasodilatory effects on the blood supply to the inner ear. 
The betahistine have weak H1-receptor agonistic and considerable H3-
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antagonistic properties in the central nervous system and autonomic nervous 
system. Many of these trials found betahistine to be effective in reducing the 
frequency in severity of vertiginous episodes and to some extent helping with 
tinnitus. No evidence exists to show betahistine helps with symptoms of hearing 
loss 23. 
Corticosteroids 
       The steroid perfusion can influence the sodium and fluid dynamics in the 
inner ear because their mineralocorticoid property. Potential advantages of 
steroid use include the low risk of complication and potential beneficial of 
hearing 24. 
Meniett device 
       Meniett device is a minimally invasive, nondestructive therapy. Its use is 
based on the observation that pressure changes applied to the inner ear result in 
beneficial changes in the symptoms of patient. The patient requires a standard 
ventilation tube to be placed before use. The Meniett device applies pulses of 
pressure to the inner ear via the ventilation tube. A treatment cycle takes 5 
minutes and is repeated 3times a day. Meniett device is a second line therapy 
when first line medical therapy failed 25. 
Gentamicin perfusion 
        In the 1990s, gentamicin perfusion/ injection emerged as a predominant 
therapy for the incapacitating of vertigo of Meniere’s disease. Gentamicin is an 
amino glycoside antibiotic that is preferentially toxic to the dark cell and hair 
cell (not so much) of the vestibular labyrinth. A variety of techniques have been 
developed to ablate the diseased labyrinth with intra tympanic gentamicin. 
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Dosage schedules and routes of administration vary considerably according to 
technique. 
       The patient is placed in the trendelenberg position with the affected ear 
turned up and head turned at a 45 degree angle. The posterior aspect of the 
tympanic membrane is anesthetized using a drop of phenol and a gentamicin 
solution (either a solution buffered with sodium bicarbonate with a gentamicin 
concentration of 30mg/cc or unbuffered solution with a gentamicin 
concentration of 40mg/cc) is injected by fine needle. The entire posterior half of 
the tympanic cavity filled with gentamicin, the creation of a pinpoint tympanic 
membrane perforation anterior to malleus allowing air escapes this process. The 
patient is left in position for 45 minutes and then discharged, with instruction to 
return in 1 week for a second injection. 
        In the majority of cases, two injections suffice to episodic vertigo. If the 
vertigo persists and there is no hearing loss, additional injection is performed.  
    The therapy is recommended only in unilateral Meniere’s disease. The 
amount of gentamicin that leaks down the Eustachian tube and is lost 
nasopharynx, escapes back to the external canal. The degree of hearing loss 
depends not only on the total dose and dose schedule, but also on the 
susceptibility of the individual to gentamicin. 
The advantages of gentamicin injection are clear. At least first several 
years, the procedure seems to achieve a vertigo control similar to that of 
vestibular neurectomy, without associated morbidity and mortality 9,6. 
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SURGICAL MANAGEMENT 
        Surgery for can be divided into auditory-sparing (conservative) and 
auditory- ablative (destructive) procedures. There are several procedures of 
historical interest that are no longer in general use.  
Sacculotomy 
       1964, Fick recommended puncture of the stapes foot plate with a sharp 
needle to rupture the under laying saccule. The procedure used a transcanal 
approach, with the elevation of a tympanomeatal flap. Long term follow up has 
revealed a considerable incidence of progressive hearing loss.  
Cochleosacculotomy 
      This approach is the permanent fistulization of the endolymphatic and 
perilymphatic spaces were devised by House (the otic – periodic shunt). The 
procedure was performed via an exploratory tympanotomy approach. In the 
otic-periotics shunt procedure, a tube was placed through the round window 
membrane to perforate the basilar membrane. In the cochleosacculotomy, a 
right angle hook was inserted through the round window membrane so as to 
cause a fracture /dislocation of the osseous spiral lamina. High incidence of 
sensorineural deafness, these procedures is rarely performed. 
Endolymphatic Sac Surgery 
             Endolymphatic sac decompression or drainage has been espoused for 
the management of endolymphatic hydrops since portmann’s in 1926. The 
procedure begins with a simple mastoidectomy with identification of the middle 
and posterior fossa dural plates, sinodural angle, sigmoid sinus, antrum, the 
horizontal semicircular canal and incus. Using a diamond bur, the facial nerve is 
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identified leaving intact a thin bony covering from the horizontal canal to the 
stylomastoid foramen. The visualization of the facial nerve enables safe removel 
of the retrofacial cells and identification of the endolymphatic sac. The posterior 
semicircular canal is next identified. Once the posterior canal has been 
identified, the posterior fossa dural plate is removed between the sigmoid sinus 
and the posterior canal. The endolymphatic sac is located by tracing an 
imaginary (Donaldson’s) line through the horizontal semicircular canal, 
perpendicular to and bisecting the posterior semicircular canal. Edge of the 
endolymphatic sac is usually located just inferior to this line. The precise 
managemement of the sac subsequent to its identification varies according to 
which procedure is conducted 10. 
In decompression of the sac, removal of all bone of the posterior fossa dural 
plate completes the procedure.  Attempts to revascularize the decompressed sac 
with a temporalis muscle pedicle flap have been abandoned. Shunting of the sac 
can be performed either into the mastoid or the subarachnoid space. House 
developed the endolymphatic subarachnoid shunt procedure, in which both 
walls of the endolymphatic sac are incised, and a specially designed silicone 
(Silastic) shunt tube is inserted into the lateral prolongation of the basal cistern.  
Labyrinthectomy 
A cortical mastoidectomy is performed. The posterior external bony canal 
wall is thinned, the bone over the tegmen is thinned, and the sigmoid sinus is 
skeletonized. The labyrinth is skeletonized and the cells of the mastoid tip are 
opened. The labyrinthectomy is performed by opening of the lateral 
semicircular canal. The lateral canal is only half opened to canal and following 
to the posterior protect the external genu of the facial nerve. The posterior canal, 
having been opened, can be traced to its confluence with the superior 
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semicircular canal, where the two canals combine to become the common crus. 
The common crus may then be followed directly forward to the vestibule. With 
all the canals and the vestibule opened, all soft-tissue elements of the 
membranous labyrinth should be removed. 
Translabyrinthine Vestibular Neurectomy 
 Mastoidectomy and labyrinthectomy are performed as previously described 
under labyrinthectomy. Exploration of the IAC is clear identification of the IAC 
contents. When dissecting the AC is to enable identification of the facial nerve 
in its normal position and extend the dissection into the diseased area. 
Once the IAC is adequately skeletonized, the thin bone over the canal is lifted 
away with a small right-angle pick. The perforated area where the superior 
vestibular nerve enters both the lateral and the superior ampullae is thinned 
carefully, and a 1-mm hook is used to avulse the superior vestibular nerve from 
the vestibular nerve recess that it makes in the labyrinthine bone lateral to the 
fallopian canal. As the superior vestibular nerve is reflected, the facial nerve 
comes into view deep to the plane of dissection.  
With the superior vestibular nerve separated from the facial nerve, the 
inferior vestibular nerve is also avulsed with the singular nerve to the posterior 
semicircular canal. Failure to include the singular nerve may cause failure of the 
operation 20. 
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Endolymphatic sac decompression           Vestibular nerve section 
 
Labyrinthectomy 
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MATERIALS    
   This study was a prospective study. Institutional ethical committee clearance 
was obtained for the study. During the study period Jan 2010 to Nov 2010, the 
patients attending the outpatient department of the Upgraded Institute of 
Otorhinolaryngology, Madras Medical College & Government General 
Hospital, and Chennai were screened for Meniere’s disease. These patients were 
explained about the study. Those who have given consent were included in the 
study as per inclusion and exclusion criteria. 
INCLUSION CRITERIA: 
People attending neuro – otologic clinic were classified into Very definite and 
Definite Meniere’s disease according to AAO HNS classification 
AAO-HNS CLASSIFICATION 
VERY DEFINITE MERIERE’S DISEASE 
 The patient has had at least two attacks of sudden vertigo has lasted more 
than 20 minutes but less than a day along with Deafness, Tinnitus, Aural 
fullness, Glycerol dehydration test positive , EcochG positive 
DEFINITE MENIERE’S DISEASE; 
 Episodic vertigo, Deafness, Tinnitus, Aural fullness, Positive glycerol 
positive test, Typical EcochG finding not present  
 
Both male and female, age > 15 years  
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EXCLUSION CRITERIA: 
People with previous ear disease like CSOM, congenital malformation, 
People with previous ear surgeries,syphilis,intracranial tumour 
People on ototoxic drugs, head injury, any other major exanthematous illness 
People with positive family history of HOH 
SAMPLE SIZE: 50 
CONTROL GROUP 
       The patients were attending neuro-otologic clinic with symptoms of 
Meniere’s disease. The patient is treated with oral betahistine. 
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METHODOLOGY 
         The Patients who attend the  neuro otologic clinic with vertigo ,tinnitus, 
fluctuate hearing loss for which to confirm Meniere’s disease by audiogram , 
glycerol test ,tone decay, SISI, ECochG.  
          Before doing glycerol test, the basic investigations like blood sugar, urea 
and ECG to be done and to avoid glycerol complication. 
       The patient should get anesthetist fitness, before going to the procedure.  
         The patient is placed in the trendelenberg position with the affected ear 
turned up and head turned at a 45 degree angle. The posterior canal wall is 
anesthetized with 2% xylocaine.  The ventilation tube is inserted in the posterior 
inferior quadrant of the tympanic membrane. 
  0.7ml of gentamicin(0.7ml=30mg/) mixed with 0.3ml of sodium bi 
carbonate solution  is injected intratympanically once a week for 3 consecutive 
weeks. If the patient came with complaints of hearing impairments after the first 
dose, the next dose should be avoided.  
  After 6 months of intratympanic gentamicin therapy, patient has to be 
evaluated using ECochG and audiogram. Patient has to be graded according to 
AAO - HNS criteria of vertigo control and hearing level changes. 
Numeric value scale        control level                            class 
   0                     complete control of definitive spells         A              
 41-80                 limited control of definitive spells           B 
81-120        insignificant control of definitive spells           C 
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>120                                                                                    D 
Secondary treatment initiated                                              E 
Hearing classification: 
 Unchanged=10d B PTA ,15% SD 
 Improved >10 d B PTA >15% SD 
 Worse >10 d B PTA worsened >15% SD worsened. 
 
The control group is also confirmed by glycerol test, ECochG.  
Statistitical analysis was made using ANOVA and Paired ‘t’ Test 
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RESULTS & ANALYSIS 
Observation of 50 patients who underwent intratympanic gentamicin therapy is 
as follows. 
AGE AND SEX DISTRIBUTION 
Age of the patients participated in this study and control is from 15 to 60 years. 
Table 1 Age Distribution 
AGE CASE % CONTROL % 
<20 3 15 3 10 
21-30 4 20 13 43 
31-40 3 15 6 20 
41-50 8 40 8 27 
51-60 2 10 0 0 
 
In sex distribution 55% to 60% is male and 43% to 45% is female. 
Table 2 Sex Distribution 
Sex 
Control Case 
Total 
Count % Count % 
F 13 43.3 8 40.0 21 
M 17 56.7 12 60.0 29 
Total 30 100.0 20 100.0 50 
p = 0.984 Not Significant 
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CLASSIFICATION 
The study and control group are classified into very definitive and definitive 
Meniere’s disease by glycerol test and ECochG. 
Table 3 Classification 
Classification 
Control Case 
Total 
Count % Count % 
Definite 13 43.3 7 35.0 20 
Very definite 17 56.7 13 65.0 30 
Total 30 100.0 20 100.0 50 
p = 0.769 
STAGING 
According to symptoms and hearing level the case and control are divided into 
4 stages. 
Table 4 Staging 
Stage 
Control Case 
Total 
Count % Count % 
I 0 0.0 4 20.0 4 
II 16 53.3 8 40.0 24 
III 13 43.3 7 35.0 20 
IV 1 3.3 1 5.0 2 
Total 30 100.0 20 100.0 50 
p = 0.081 
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GLYCEROL TEST 
The glycerol test is positive in side of the ear of both cases and controls. 
Table 5 Glycerol Test 
Glycerol Test 
Control Case 
Total 
Count % Count % 
Lt-+Ve 14 46.7 9 45.0 23 
Rt-+Ve 16 53.3 11 55.0 27 
Total 30 100.0 20 100.0 50 
P=0.998 
 
ELECTROCOCHLEARGRAM 
Both pre operative and post operative ECochG are taken. In the control group 
only pre treatment ECochG are taken. 
Table 6 Pre operative and post operative ECochG 
EcochG SP/AP Post op EcochG 
t Df p value 
Mean N S D Mean N S D 
0.43 20 0.29 0.328 20 0.24 3.82 19 0.001 
 
 
Table 7 Case vs Control 
  
Case Control T Df p 
value 
N Mean S D N Mean S D 
EcochG 
SP/AP 
20 0.43 0.29 30 0.40 0.28 0.30 48 0.768 
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Glycerol Test 
 
BOX-PLOT Curve comparing Case vs Control and the Pre-op and Post-op 
EcochG in the Case group 
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Table 8 Case Summaries 
Case Age 
EcochG 
SP/AP 
Post op 
EcochG 
Control 
N 30 30  
Mean 32.40 .40  
Std. 
Deviation 
10.759 .285  
Minimum 18 0  
Maximum 50 1  
Case 
N 20 20 20 
Mean 37.10 .43 .32800 
Std. 
Deviation 
12.578 .290 .239310 
Minimum 17 0 .010 
Maximum 57 1 .800 
Total 
N 50 50 20 
Mean 34.28 .41 .32800 
Std. 
Deviation 
11.630 .284 .239310 
Minimum 17 0 .010 
Maximum 57 1 .800 
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                                             VERTIGO CONTROL 
After 6 months of therapy, both case and control are clinically evaluated by 
AAO-HNS guidelines. 
Table 9 Vertigo Control 
Vertigo 
Control 
Control Case 
Total 
Count % Count % 
A 9 30.0 12 60.0 21 
B 12 40.0 7 35.0 19 
C 5 16.7 0 0.0 5 
D 4 13.3 0 0.0 4 
E 0 0.0 1 5.0 1 
Total 30 100.0 20 100.0 50 
p = 0.038 Significant 
 
HEARING LEVEL CONTROL 
Both case and control are evaluated by audiogram. 
Table 10 Hearing level 
Hearing Level 
Control Case 
Total 
Count % Count % 
Unchanged 28 93.3 18 90.0 46 
Worsen  
> 10 dB 
2 6.7 2 10.0 4 
Total 30 100.0 20 100.0 50 
p = 0.987 
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DISCUSSION 
      Despite many years of research, the exact cause of MD remains elusive. 
Medical management is the mainstay of treatment of MD. Further research is 
required to evaluate the effect of treatments. Chemical labyrinthectomy using 
aminoglycosides is an effective alternative to second line treatment for those 
patients in whom medical management is unsuccessful. 
    This study of 20 case and 30 control patient over the period from Jan 2010 to 
Nov 2010. They included in the case group 40% of male and 60% of female, 
like wise in the control group 56.7% of male and 43.3% of female. 
    The patient came with episodic vertigo, fluctuating hearing loss, aural 
fullness and tinnitus were included in the study, and they were staged by their 
symptom and audiogram. 
    In both the study group and the control group the patient presented maximum 
at Stage II. Though none of the study population belonged to Stage I, in 
comparison to 20 % of the control population, this was not statistically 
significant (p=0.08) 
     The study and control group were diagnosed into very definitive and definite 
Meniere’s disease by glycerol test and ECochG 
        In this study 65% of patient was diagnosed very definitive Meniere’s 
disease and 35% was diagnosed definitive Meniere’s disease. In the control 
group 55% of the patient was diagnosed very definitive Meniere’s disease and 
45% of the patient was diagnosed definitive Meniere’s disease. 
      The study group was treated with intatympanic gentamicin therapy 3 times 
at weekly interval, while the control group was treated with oral betahistine. 
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At the end of the study period ECochG was taken for the study group and 54% 
of patient reverted to normal ECochG. 
      In the study group 90% of patient showed no changes in hearing level, and 
10% of patient showed worsening of hearing level. This was insignificant when 
compared to the control group. (p=0.987) 
     In the study group, the patient was in vertigo control level A 60%, B 35% 
and E 5% (n=1) of patient had gone for secondary surgical management. In the 
control group, the patient was in vertigo control level  A 30%, B 40%, C 16.7%, 
D 13.3% which was significant (p=0.038) suggesting a better vertigo control in 
the cases. 
   In the US study, Kaasinen and colleagues were one of the first groups to 
publish a large series in which the AAO-HNS guidelines were followed. A total 
of 93%patients treated with transtympanic gentamicin for MD. Rotatory vertigo 
was abolished in 81% of patients treated. 10% patients suffered dead ears as a 
response to treatment, and mean pure tone average decreased by 8.8 dB. 
     Cohen-kerem and colleagues under look a meta-analysis that combined the 
result of 15 trials in which the AAO-HNS guidelines for reporting treatment 
results in MD were used. This analysis represented 627 patients. Class A vertigo 
control was achieved in 74.7% of patients and class B in 92.7% of patient. 
     In articles reporting results from patient treated with fixed dose protocol, the 
overall success rate was 68.7% for class A control and 91.9% for class B 
control. 
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Driscoll and colleagues using a treatment regimen consisting of a single 
gentamicin injection, result of short term control of vertigo in 85%, with a 5 to 
10% acute hearing loss related to injection (4). 
        A larger series consisting of 90 patients, using the same treatment regimen, 
was published in 1996. A total of 85% of patients reported complete vertigo 
control and 9% reported substantial vertigo control. Hearing loss occurred in 
23% of patients; 165 of patients suffered a severe to profound hearing loss 
which was contradictory to our research which showed only a statistically 
insignificant 10% (n=2) 
        The most recent study, in which the minimum follow-up time after 
treatment was 5 years and the average follow-up time was 15.5 years, again 
showed consistently good vertigo control.  
Thus my study showed a vertigo control of 60% relatively the same as 
above mentioned studies which showed a vertigo control of 60 to 75%. 
In my study 10% of patients showed worsening of hearing level while the 
above mentioned studies showed 10-23% worsening of hearing level. 
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                                             CONCLUSION 
      In this study 60% of patients were diagnosed with very definite Meniere’s 
disease and 40% of patients were diagnosed definite Meniere’s disease using 
ECochG.    
       In this study 60% of patients showed improvements of vertigo control with 
intratympanic gentamicin therapy, while in control group only 30% of patients 
showed improvements.       
      My study shows that intatympanic gentamicin therapy is more effective in 
controlling vertigo in Meniere’s disease patients. 
      Post intra tympanic gentamicin therapy ECochG was significantly 
improved. 
     In this study 10% of patients showed worsening of hearing level with 
intratympanic gentamicin therapy, while in 6.7% of patients showed worsening 
of hearing with oral therapy. 
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PROFORMA  
DATE: 
 NAME:    AGE:    SEX: M/F OP NO                             
ADDRESS:    OCCUPATION:  STUDY NO: 
Presenting Complaint: 
Giddiness Unsteadiness  HOH  Tinnitus           Headache
         
Examination: 
                      HOH          Tinnitus  Ears: 
Duration                          Nose: 
Side                         Throat: 
Sudden       Fistula Test: 
Progressive 
Fluctuating       
Vestibular system: 
INVESTICATIONS: 
BLOOD SUGUR, UREA, X-RAY CHEST, ECG 
PURE TONE AUDIOGRAM 
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TONE DECAY, SISI,  
GLYCEROL TEST 
ELECTROCOCHLEOGRAPHY    STAGE:            CLASSIFICATION: 
POST GENTAMICIN THEREPY 
ELECTROCOCHLUOGRAPHY, AUDIOGRAM,     HEARING LEVEL:   
VERTIGO CONTROL: 
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ABBREVIATION 
MD          -         MENIERE’S DISEASE 
SISI          -         SHORT INCRIMATION SENSITIVE INDEX 
CPA         -         CEREBELLO PONTINE AGCLE 
SD            -        SPEECH DISCRIMINATION 
PTA         -        PURE TONE AVERAGE 
VOR        -        VESTIBULO OCULAR REFLEX 
SP           -          SUMMATION POTENTIAL 
AP           -          ACTION POTENTIAL 
CM          -          COCHLEAR MICROPHONY 
VEMP     -      VESTIBULAR EVOKED MYOGENIC POTENTIAL 
SISI      -     SHORT INCREMENT SENSITIVITY TEST 
ABLB   -     ALTERNATE BINAURAL LOUDNESS BALANCE TEST 
TDT     -      TONE DECAY TEST 
SCM    -       STERNOCLEDO MASTOID 
EAM   -        EXTERNAL AUDITORY MEATUS 
TM     -         TYMPANIC MEMBRANE 
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1 Selvaraj 1 25 M 20404 
Very 
definite 
II Lt-32dB Lt-+Ve 
TDT- 
Ve 
SISI 
70% 
0.60 0.32 A Unchanged 
2 Vishalatchi 1 41 F 22135 Definite III Rt-46dB Rt-+Ve 
TDT- 
Ve 
SISI -
90% 
0.05 0.05 B Unchanged 
3 Kandhan 1 19 M 52075 Definite II Lt-28dB Lt-+Ve 
TDT- 
Ve 
SISI -
80% 
0.04 0.04 A Unchanged 
4 Kanthurubi 1 50 F 10378 
Very 
definite 
III Rt-52dB Rt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.70 0.70 E 
Worsen  
> 10 dB 
5 Manimagalai 1 32 F 90701 
Very 
definite 
II Rt-30dB Rt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.60 0.29 A Unchanged 
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6 Thulasi Bai 1 48 F 13843 Definite III Lt-50dB Lt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.02 0.01 B Unchanged 
7 Vediyammal 1 28 F 7049 
Very 
definite 
III Lt-45dB Lt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.60 0.60 A Unchanged 
8 Rani 1 40 F 25933 
Very 
definite 
III Rt-48dB Rt-+Ve 
TDT- 
Ve 
SISI -
100% 
0.50 0.40 B Unchanged 
9 Alagiri 1 52 M 8092 Definite IV Lt-64dB Lt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.03 0.03 B 
Worsen  
> 10 dB 
10 Sunmugasundharam 1 50 M 38214 
Very 
definite 
II Lt-40dB Lt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.80 0.60 A Unchanged 
11 Tamilarasu 1 17 M 12267 
Very 
definite 
I Rt-24dB Rt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.47 0.30 A Unchanged 
12 Sakil Ahmed 1 45 M 12671 Definite II Lt-35dB Lt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.06 0.04 A Unchanged 
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13 Rajendran 1 41 M 8322 
Very 
definite 
I Rt-22dB Rt-+Ve 
TDT- 
Ve 
SISI -
70% 
1.01 0.80 B Unchanged 
14 Mani 1 40 M 25933 Definite II Rt-34dB Rt-+Ve 
TDT- 
Ve 
SISI -
100% 
0.10 0.10 A Unchanged 
15 Nirmal Raj 1 45 M 2401 
Very 
definite 
I Rt-16dB Rt-+Ve 
TDT- 
Ve 
SISI -
100% 
0.49 0.30 A Unchanged 
16 Meera 1 57 F 12238 Definite II Rt-32dB Rt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.29 0.29 B Unchanged 
17 Senthil 1 21 M 8749 
Very 
definite 
I Rt-18dB Rt-+Ve 
TDT- 
Ve 
SISI -
100% 
0.60 0.30 A Unchanged 
18 Stalin 1 25 M 9944 
Very 
definite 
II Lt-34dB Lt-+Ve 
TDT- 
Ve 
SISI -
80% 
0.47 0.41 A Unchanged 
19 Kasturi 1 46 F 12801 
Very 
definite 
III Lt-52dB Lt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.60 0.60 B Unchanged 
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20 Gopalakrishnan 1 20 M 26075 
Very 
definite 
III Rt-55dB Rt-+Ve 
TDT- 
Ve 
SISI -
80% 
0.48 0.38 A Unchanged 
1 mohammed ansari 0 37 m 2074 Definite II Rt-30dB Rt-+Ve 
TDT- 
Ve 
SISI 
70% 
0.30   A Unchanged 
2 manika valli 0 46 f 4801 Definite II Rt-28dB Rt-+Ve 
TDT- 
Ve 
SISI 
>60% 
0.05   B Unchanged 
3 kumeresan 0 24 m 2083 
Very 
definite 
III Lt-40dB Lt-+Ve 
TDT- 
Ve 
SISI 
>60% 
0.40   C 
Worsen  
> 10 dB 
4 Natarajan 0 44 m 4056 
Very 
definite 
II Lt-18-Db Lt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.70   B Unchanged 
5 Neela 0 50 f 3181 Definite II Rt-30dB Rt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.31   A Unchanged 
6 john kennedy 0 48 m 3089 Definite III Lt-50dB Lt-+Ve 
TDT- 
Ve 
SISI -
60% 
0.02   C Unchanged 
67 
 
7 kurshith 0 50 m 4178 
Very 
definite 
II Rt-26dB Rt-+Ve 
TDT- 
Ve 
SISI -
60% 
0.60   A Unchanged 
8 chinnaponnu 0 30 f 1086 Definite IV Lt-56dB Lt-+Ve 
TDT- 
Ve 
SISI -
100% 
0.21   B Unchanged 
9 valliammal 0 44 f 2481 
Very 
definite 
II Rt-30dB Rt-+Ve 
TDT- 
Ve 
SISI -
60% 
0.70   B Unchanged 
10 sethu 0 22 m 4186 
Very 
definite 
III Lt-40dB Lt-+Ve 
TDT- 
Ve 
SISI -
60% 
O.7   A Unchanged 
11 subash 0 33 m 2100 
Very 
definite 
II Rt-24dB Rt-+Ve 
TDT- 
Ve 
SISI -
60% 
0.42   B Unchanged 
12 hajeera 0 18 f 3319 Definite II Lt-22dB Lt-+Ve 
TDT- 
Ve 
SISI -
60% 
0.06   B Unchanged 
13 divakar 0 21 m 2710 
Very 
definite 
III Rt-46dB Rt-+Ve 
TDT- 
Ve 
SISI -
60% 
1.01   D Unchanged 
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14 Joonath 0 34 f 3789 
Very 
definite 
II Lt-20dB Lt-+Ve 
TDT- 
Ve 
SISI -
100% 
0.10   A Unchanged 
15 Rani 0 48 f 2121 
Very 
definite 
III Rt-56dB Rt-+Ve 
TDT- 
Ve 
SISI -
100% 
0.43   D Unchanged 
16 Mahesh 0 30 m 2801 Definite II Rt-26dB Rt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.29   B Unchanged 
17 inbasekaran 0 30 m 4329 
Very 
definite 
III Rt-50dB Rt-+Ve 
TDT- 
Ve 
SISI -
100% 
0.60   A Unchanged 
18 Kalyani 0 22 f 5544 Definite II Lt-34dB Lt-+Ve 
TDT- 
Ve 
SISI -
80% 
0.04   C Unchanged 
19 Riswan 0 23 m 3415 
Very 
definite 
III Lt-52dB Lt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.60   B Unchanged 
20 dhanalakshmi 0 38 f 1643 Definite III Rt-55dB Rt-+Ve 
TDT- 
Ve 
SISI -
80% 
0.24   C Unchanged 
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21 singaram 0 18 m 6086 Definite III Lt-40dB Lt-+Ve 
TDT- 
Ve 
SISI -
60% 
O.7   A Unchanged 
22 jeevarathinam 0 36 m 26800 
Very 
definite 
II Rt-24dB Rt-+Ve 
TDT- 
Ve 
SISI -
60% 
0.42   B Unchanged 
23 manjula 0 18 f 43316 Definite II Lt-22dB Lt-+Ve 
TDT- 
Ve 
SISI -
60% 
0.06   B Unchanged 
24 sanker 0 21 m 25890 
Very 
definite 
III Rt-46dB Rt-+Ve 
TDT- 
Ve 
SISI -
60% 
1.01   D Unchanged 
25 devi 0 34 f 9123 
Very 
definite 
II Lt-20dB Lt-+Ve 
TDT- 
Ve 
SISI -
100% 
0.10   A Unchanged 
26 vasumathi 0 48 f 66571 
Very 
definite 
III Rt-56dB Rt-+Ve 
TDT- 
Ve 
SISI -
100% 
0.43   D Unchanged 
27 panneer 0 30 m 12645 Definite II Rt-26dB Rt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.29   B Unchanged 
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28 setu 0 30 m 69102 
Very 
definite 
III Rt-50dB Rt-+Ve 
TDT- 
Ve 
SISI -
100% 
0.60   A Unchanged 
29 mercy 0 22 f 64839 Definite II Lt-34dB Lt-+Ve 
TDT- 
Ve 
SISI -
80% 
0.04   C Unchanged 
30 sethupathi 0 23 m 45781 
Very 
definite 
III Lt-52dB Lt-+Ve 
TDT- 
Ve 
SISI -
70% 
0.60   B Unchanged 
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PATIENT CONSENT FORM 
Study Detail: EFFECT OF INTRA TYMPANIC GENTAMICIN THERAPY IN 
MENIERE’S DISEASE  
Study Centre: Upgraded Institute of Otorhinolaryngology, 
   Madras Medical Collage & Government General Hospital, 
Chennai-3 
Patient Name                   : 
Patient Age            : 
Identification Number : 
        Patient may tic (  ) these 
boxes 
 I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask the question and all my questions and 
doubts have been answered to my satisfaction. 
 I understand that my participation in the study is voluntary and that I am 
free to withdraw at anytime without giving any reason, without my legal rights 
being effected. 
I understand that Investigator, Regulatory authorities and the Ethics 
committee will not need my permission to look at my health records both in 
respect to the current study and any further research that may be conducted in 
relation to it, even if withdraw from the study. I understand that my identity will 
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not be revealed in any information released to third parties or published, unless 
as required under the law. I agree not to restrict the use of any data or results 
that arise from the study.  
I was informed about the proceedings of study and any unwanted 
consequences like hearing loss that can happen in the course of the study. I 
agree to take part in the above study and to comply with the instructions given 
and faithfully co- operates with the study team. I agree to inform the study staff 
immediately if I suffer from any deterioration in my health or well being or any 
unexpected or unusual symptoms.  
 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological tests. 
Signature/Thumb Impression:    Place:   Date: 
Patient Name and Address    :     
 
Signature of the Investigator:    Place:   Date: 
Study Investigator’s Name    : 
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INSTITUTIONAL ETHICAL COMMITTEE 
MADRAS MEDICAL COLLEGE, CHENNAI - 3 
 
Telephone No : 044 25305301 
 Fax                 : 044 25363970 
 
CERTIFICATE OF APPROVAL 
 
To 
Dr. V. Suresh 
PG in MS ENT 
Madras Medical College, Chennai -3 
 
Dear Dr. V. Suresh 
 
The Institutional Ethical Committee of Madras Medical College reviewed and discussed               
your application for approval of the project I proposal / clinical trial entitled “ Effect of intratympanic 
gentamycin therapy in meniere’s disease” No 16072010 
 
The following members of Ethical committee were present in the meeting held on 21.07.2010 
conducted at Madras Medical College, 
 
1.   Prof. S.K. Rajan, MD -  Chairperson 
2.   Prof. J. Mohanasundaram, MD,Ph.D,DNB -  Deputy Chairman 
      Dean, Madras Medical College, Chennai -3 
3.   Prof. A. Sundaram, MD - Member Secretary 
      Vice Principal MMC, Chennal -3 
4.   Prof R. Sathianathan, MD -  Member 
      Director, Institute of Psychiatry 
5.   Prof R. Nandhini, MD -  Member 
      Director Institute of Pharmacology, M MC, Ch-3 
6.   Prof Pregna B. Dolia, MD -  Member 
      Director, Institute of Biochemistry, MMC, Ch-3 
7.   Prof. C. Rajendran, MD -  Member 
      Director, Institute of Internal Medicine, MMC, Ch-3 -  Member 
8.   Prof. Geetha Subramanian, MD,DM -  Member 
      Professor & Head, Dept. Of Cardiology 
9.   Prof. V. Shruti Kamal, MS -  Member 
      Professor of Surgery, MMC, Ch-3 
10. Prof Md. Au, MD, DM -  Member 
      Professor & Head ,,Dept. of MGE, MMC, Ch-3 -  Member 
 
We approve the trail to be conducted in its presented form. 
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Sd/. Chairman & Other Members 
 
The Institutional Ethics Committee expects to be informed about the progress of the study, any SAE 
occurring in the course of the study, any changes in the protocol and patient information / informed 
consent and asks to be provided a copy of the final report 
 
                                                                                
 
Member Secretary, Ethics Committee. 
 
